SLC18A2 Protein

📖 Wiki Page

protein837 wordssynced 2026-04-02

SLC18A2 Protein

Introduction

Slc18A2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Vesicular Monoamine Transporter 2 [@zheng2019]

<div class="infobox infobox-protein"> [@caudle2007]
<div class="infobox-header">SLC18A2 Protein</div> [@guo2021]
<div class="infobox-content"> [@taylor2012]
| Property | Value |
|---------|-------|
| Protein Name | Vesicular Monoamine Transporter 2 |
| Gene | SLC18A2 (VMAT2) |
| UniProt | Q9H3K1 |
| Molecular Weight | ~56 kDa |
| Subcellular Localization | Synaptic vesicle membrane (presynaptic terminals) |
| Protein Family | SLC18 (vesicular amine transporter) |
| Aliases | VMAT2, VAT2 |
</div>
</div>

Overview

SLC18A2 (also known as VMAT2, Vesicular Monoamine Transporter 2) is a critical synaptic vesicle protein responsible for packaging monoamine neurotransmitters into vesicles for subsequent release[@lohr2020]. This transporter is essential for dopamine, serotonin, norepinephrine, epinephrine, and histamine neurotransmission[@zheng2019]. VMAT2 is a major therapeutic target for Parkinson's disease and other movement disorders[@caudle2007].

Structure

VMAT2 is a 12-transmembrane domain protein localized to synaptic vesicle membranes[@guo2021]:

...

SLC18A2 Protein

Introduction

Slc18A2 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Vesicular Monoamine Transporter 2 [@zheng2019]

Overview

Structure

VMAT2 is a 12-transmembrane domain protein localized to synaptic vesicle membranes[@guo2021]:

Transmembrane domains 1-12: Form the transmembrane pore for amine transport
Cytosolic N-terminus: Contains trafficking signals
Vesicular lumen C-terminus: Contains regulatory domains
Proton gradient binding sites: VMAT2 uses the V-ATPase proton gradient as energy source

The transporter operates as an antiporter, exchanging cytoplasmic monoamines for lumenal protons[@taylor2012].

Function in Monoamine Neurotransmission

Vesicular Packaging

VMAT2 is responsible for packaging monoamine neurotransmitters into synaptic vesicles[^6]:

After dopamine is synthesized in the cytoplasm by tyrosine hydroxylase

VMAT2 transports dopamine into synaptic vesicles using the proton gradient

This creates a high concentration of dopamine within vesicles

Upon neuronal firing, vesicles fuse with the presynaptic membrane

Dopamine is released into the synaptic cleft

Monoamine Substrate Specificity

VMAT2 transports multiple monoamines with varying efficiency:

| Neurotransmitter | Relative Affinity | Brain Regions |
|-----------------|-------------------|---------------|
| Dopamine | High | Nigrostriatal, mesolimbic |
| Serotonin | High | Raphe nuclei |
| Norepinephrine | Moderate | Locus coeruleus |
| Histamine | Moderate | Hypothalamus |

Role in Parkinson's Disease

VMAT2 Dysfunction in PD

VMAT2 dysfunction is implicated in Parkinson's disease pathogenesis[^7]:

Reduced VMAT2 levels: Post-mortem studies show decreased VMAT2 in PD brains
Vulnerability mechanism: Lower VMAT2 leads to increased cytosolic dopamine oxidation
Alpha-synuclein interaction: α-Synuclein may directly inhibit VMAT2 function

VMAT2 as Therapeutic Target

Multiple therapeutic strategies target VMAT2[^8]:

| Strategy | Example | Mechanism |
|----------|---------|-----------|
| VMAT2 inhibitors | Tetrabenazine, valbenazine | Deplete vesicular dopamine |
| VMAT2 enhancers | None currently | Increase VMAT2 expression/function |

Tetrabenazine and VMAT2

Tetrabenazine: FDA-approved VMAT2 inhibitor for Huntington's chorea
Depletes dopamine: Reduces involuntary movements by decreasing dopamine release
Side effects: Depression, sedation, Parkinsonism
Valbenazine: More selective VMAT2 inhibitor with better tolerability

Neuroprotective Strategies

Enhancing VMAT2 Function

Potential neuroprotective approaches[^9]:

Gene therapy: AAV-VMAT2 to increase vesicular dopamine capacity
Small molecule activators: Compounds that enhance VMAT2 trafficking/function
Combination therapy: VMAT2 enhancement with other neuroprotective agents

VMAT2 and Oxidative Stress

Cytoprotection: Adequate VMAT2 function reduces cytosolic dopamine
Oxidative stress: Cytosolic dopamine oxidizes to form toxic quinones
Neuroprotection: Preserving VMAT2 may protect against oxidative damage

Disease Associations

| Disease | Association | Evidence |
|---------|-------------|----------|
| Parkinson's Disease | VMAT2 deficiency | Reduced VMAT2 binding in imaging studies[^10] |
| Huntington's Disease | VMAT2 inhibition | Tetrabenazine treatment reduces chorea |
| ADHD | VMAT2 polymorphisms | Genetic association studies |
| Depression | VMAT2 function | Target of some antidepressants |

Key Publications

Eiden LE, et al. (2004). "VMAT2: a dynamic phosphoprotein." J Mol Neurosci.[@lohr2020]

Liu Y, et al. (2012). "Vesicular monoamine transporter 2: role in neurodegeneration." Neurochem Int.[@zheng2019]

Guillot TS, et al. (2008). "VMAT2 and Parkinson's disease." Auton Neurosci.[@caudle2007]

Background

The study of Slc18A2 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[UniProt: Q9H3K1](https://www.uniprot.org/uniprot/Q9H3K1)
[GeneCards: SLC18A2](https://www.genecards.org/cgi-bin/carddisp.pl?gene=SLC18A2)
[OMIM: 193001](https://www.omim.org/entry/193001)

References

[Lohr KM, Stout J, Grimm MS, et al. "Vesicular Monoamine Transporter 2 (VMAT2) as a Therapeutic Target for Parkinson's Disease." Neuropharmacology, 2020;168:108017 (2020)](https://pubmed.ncbi.nlm.nih.gov/32027910/)

[Zheng H, Law PY, Friedman M, et al. "VMAT2 and Dopamine Neuron Resilience." J Neurosci, 2019;39(46):9071-9077 (2019)](https://pubmed.ncbi.nlm.nih.gov/31467173/)

[Caudle WM, Richardson JR, Wang MZ, et al. "Reduced Vesicular Storage of Dopamine Causes Progressive Nigrostriatal Neurodegeneration." J Neurosci, 2007;27(30):8138-8148 (2007)](https://pubmed.ncbi.nlm.nih.gov/17652604/)

[Guo L, Xiong M, Kim JI, et al. "Cytosolic HMGB1 Controls the Cellular Machinery for Trafficking and Degradation of VMAT2." J Cell Biol, 2021;220(5):e202009154 (2021)](https://pubmed.ncbi.nlm.nih.gov/33764394/)

[Taylor TN, Caudle WM, Shepherd KR, et al. "Nonmotor Symptoms in VMAT2 Deficiency." Mov Disord, 2012;27(6):704-712 (2012)](https://pubmed.ncbi.nlm.nih.gov/22451203/)

📖 View canonical wiki page →

SLC18A2 Protein

SLC18A2 Protein

Introduction

Overview

Structure

SLC18A2 Protein

Introduction

Overview

Structure

Function in Monoamine Neurotransmission

Vesicular Packaging

Monoamine Substrate Specificity

Role in Parkinson's Disease

VMAT2 Dysfunction in PD

VMAT2 as Therapeutic Target

Tetrabenazine and VMAT2

Neuroprotective Strategies

Enhancing VMAT2 Function

VMAT2 and Oxidative Stress

Disease Associations

Key Publications

See Also

Background

External Links

References